Vor Biopharma
Focus: Vor Biopharma is a clinical-stage biotech focused on CAR-T stem cell therapy and gene therapy, headquartered in Cambridge, MA. The company is advancing multiple late-stage programs in cell therapy and autoimmune disease.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Open Jobs
1-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Vor Biopharma?
AI assessmentVor is a high-risk, high-reward mid-stage biotech with strong clinical momentum and financial runway, best suited for professionals comfortable with platform-stage execution risk in exchange for equity upside.
Why Work Here
- Four Phase 3 programs in advanced development provide near-term value inflection opportunities and visibility into regulatory milestones.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT05309733A Long-term Follow-up Study of Patients Who Received VOR33
N/AHelp build intelligence for Vor Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.